Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1933-1937

  De Strooper, Lise M A ^a   Hesselink, Albertus T ^a   Berkhof, Johannes ^a   Meijer, Chris J L M ^a   Snijders, Peter J F ^a   Steenbergen, Renske D M ^a   Heideman, Daniëlle A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CADM1 GENE; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; DNA METHYLATION; FEMALE; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAL GENE; NONHUMAN; ONCOGENE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; EARLY DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; MAL PROTEIN, HUMAN; MYELIN AND LYMPHOCYTE PROTEIN; TUMOR MARKER;

ADULT; CELL ADHESION MOLECULES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOGLOBULINS; MIDDLE AGED; MYELIN AND LYMPHOCYTE-ASSOCIATED PROTEOLIPID PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84907168663     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0347     Document Type: Article

References (19)

1. Priebe AM. 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin Obstet Gynecol 2013; 56: 44-50.
2. Berkhof J, Coupé VMH, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJF, et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 2010; 127: 2147-58.
3. Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 2013; 25: 11-6.
4. Gezondheidsraad. Screening op baarmoederhalskanker. Den Haag, the Netherlands: gezondheidsraad; 2011. 2011/07: ISBN 978-90- 5549-841-3.
5. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee Fung M, Gzik D, et al. HPV testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol Can 2012; 34: 443-52.
6. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupé VMH, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNApositive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
7. Dijkstra M, van Niekerk D, Rijkaart D, van Kemenade FJ, Heideman DAM, Snijders PJF, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen positive women? A POBASCAM Trial sub study. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
8. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009; 112: 293-9.
9. Overmeer RM, Louwers JA, Meijer CJLM, vanKemenade FJ, Hesselink AT, Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J cancer 2011; 129: 2218-25.
10. Steenbergen RDM, Snijders PJF, Heideman DAM, Meijer CJLM. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14: 395-405.
11. Hesselink AT, Heideman DAM, Steenbergen RDM, Coupé VMH, Overmeer RM, Rijkaart D, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-65.
12. Bierkens M, Hesselink AT, Meijer CJLM, Heideman DAM, Wisman GBA, van der Zee AGJ, et al.CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J cancer 2013; 133: 1293-9.
13. Eijsink JJH, Lendvai Á, Deregowski V, KlipHG, Verpooten G, Dehaspe L, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012; 130: 1861-9.
14. Bulkmans NWJ, Rozendaal L, Snijders PJF, Voorhorst FJ, Boeke AJP, Zandwijken GRJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int J Cancer 2004; 110: 94-101.
15. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJLM. The Dutch CISOE-a framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 388-93.
16. Hesselink AT, Heideman DAM, Steenbergen RDM, Gök M, van Kemenade FJ, Wilting SM, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014; 135: 880-6.
17. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS ONE 2014; 9: e91905.
18. Rebolj M, van Ballegooijen M, Berkers L-M, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120: 806-12.
19. Snellenberg S, De Strooper LMA, Hesselink AT, Meijer CJLM, Snijders PJF, Heideman DAM, et al. Development of a multiplex methylationspecific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer 2012; 12: 551.